MAPT and Alzheimer disease: Notably, as shown in this present study, the optimal biomarker cutoffs for AD pathology in DS differ; p-tau217 levels were substantially higher in the DS compared to the euploid cohort, which might be due to a higher amyloid and tau burden in DS28,29.